All News

The initiative will provide information about care models for specialists and clinical teams to improve patient outcomes in heart failure.

Encorafenib in combination with cetuximab and mFOLFOX6 met its dual primary end point of overall response rate of 61%.

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board for a different approach.

Gold bagging integrates health system-owned specialty pharmacies with clinical workflows to enhance safety, efficiency, outcomes, and patient experience.

NK is a degenerative corneal disease resulting from diminished corneal innervation.

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

The study results build on the “obesity paradox,” which suggests that patients with cancer and obesity have better outcomes.

Nivolumab plus ipilimumab demonstrated a 38% reduction in the risk of disease progression or death.

An inverse relationship was observed between genetic conditions associated with high levels of low-density lipoprotein cholesterol and the risk of developing T2D.

Investigators noted that the differences between the 3 respiratory infections were not as pronounced during the 2023-2024 season.

Investigators found that 60% of individuals with type 2 diabetes are vitamin D deficient.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

In the study, 50% of the deaths amongst patients were linked to central nervous system-related causes.

The results highlight hemoglobin A1c/high-density lipoprotein cholesterol as a potential clinical marker for long-term stroke risk.

Some risk factors for chronic kidney disease (CKD) in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) were renal impairment, delayed diagnosis, and hypertension.

For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.

Overall, there is no long-term increased risk of developing thyroid cancer after initiating treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, although there is a short-term increase.

Angiotensin receptor neprilysin inhibitors show promise as an alternative to standard management of resistant hypertension.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

World Cancer Day, observed annually on February 4th, is a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to cancer care, with pharmacy professionals playing a vital role in prevention, treatment, and support for patients and communities.

Tocilizumab-anoh is expected to increase competition, improve patient access, and deliver cost savings in the treatment of various inflammatory conditions.

Topical, targeted drug delivery increases drug concentrations at the desired site while also reducing toxicity and unwanted adverse effects.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

Antiviral treatments can accelerate healing and reduce complications.

Three experts from UPMC Health Plan highlight the importance of treating patients’ physical, mental, and social health when managing diabetes, rather than the disease alone.

The phase 1b/2a results show the potential of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Many patients do not attain sufficient disease control with inhaled corticosteroids in combination with long-acting β-2 agonists and remain vulnerable to exacerbations.